Likelihood methods for measuring statistical evidence.
Focused on interpreting data as statistical evidence, the evidential paradigm uses likelihood ratios to measure the strength of statistical evidence. Under this paradigm, re-examination of accumulating evidence is encouraged because (i) the likelihood ratio, unlike a p-value, is unaffected by the number of examinations and (ii) the probability of observing strong misleading evidence is naturally low, even for study designs that re-examine the data with each new observation. Further, the controllable probabilities of observing misleading and weak evidence provide assurance that the study design is reliable without affecting the strength of statistical evidence in the data. This paper illustrates the ideas and methods associated with using likelihood ratios to measure statistical evidence. It contains a comprehensive introduction to the evidential paradigm, including an overview of how to quantify the probability of observing misleading evidence for various study designs. The University Group Diabetes Program (UGDP), a classic and still controversial multi-centred clinical trial, is used as an illustrative example. Some of the original UGDP results, and subsequent re-analyses, are presented for comparison purposes.
Blume
Jeffrey D
JD
Center for Statistical Sciences, Brown University, Providence, RI 02912, USA. jblume@stat.brown.edu
D001699:Biometry / Q000379:methods*; D002318:Cardiovascular Diseases / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D019317:Evidence-Based Medicine / Q000379:methods*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016013:Likelihood Functions; D015337:Multicenter Studies as Topic / Q000379:methods; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D014044:Tolbutamide / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D014044:Tolbutamide